136 related articles for article (PubMed ID: 11685384)
1. P300 and symptom improvement in schizophrenia.
Gallinat J; Riedel M; Juckel G; Sokullu S; Frodl T; Moukhtieva R; Mavrogiorgou P; Nisslé S; Müller N; Danker-Hopfe H; Hegerl U
Psychopharmacology (Berl); 2001 Oct; 158(1):55-65. PubMed ID: 11685384
[TBL] [Abstract][Full Text] [Related]
2. Effects of olanzapine on auditory P300 in schizophrenia.
Gonul AS; Suer C; Coburn K; Ozesmi C; Oguz A; Yilmaz A
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):173-7. PubMed ID: 12551741
[TBL] [Abstract][Full Text] [Related]
3. P300 subcomponents reflect different aspects of psychopathology in schizophrenia.
Frodl-Bauch T; Gallinat J; Meisenzahl EM; Möller HJ; Hegerl U
Biol Psychiatry; 1999 Jan; 45(1):116-26. PubMed ID: 9894583
[TBL] [Abstract][Full Text] [Related]
4. Long-term olanzapine treatment and p300 parameters in schizophrenia.
Molina V; Muñoz F; Martín-Loeches M; Casado P; Hinojosa JA; Iglesias A
Neuropsychobiology; 2004; 50(2):182-8. PubMed ID: 15292675
[TBL] [Abstract][Full Text] [Related]
5. P300 alterations in schizophrenic patients experiencing auditory hallucinations.
Papageorgiou C; Oulis P; Vasios C; Kontopantelis E; Uzunoglu N; Rabavilas A; Christodoulou GN
Eur Neuropsychopharmacol; 2004 May; 14(3):227-36. PubMed ID: 15056482
[TBL] [Abstract][Full Text] [Related]
6. Multilead quantitative electroencephalogram profile and cognitive evoked potentials (P300) in healthy subjects after a single dose of olanzapine.
Hubl D; Kleinlogel H; Frölich L; Weinandi T; Maurer K; Holstein W; Czekalla J; Dierks T
Psychopharmacology (Berl); 2001 Nov; 158(3):281-8. PubMed ID: 11713618
[TBL] [Abstract][Full Text] [Related]
7. Clinical and neuropsychological correlates of the P300 in schizophrenia.
Nieman DH; Koelman JH; Linszen DH; Bour LJ; Dingemans PM; Ongerboer de Visser BW
Schizophr Res; 2002 May; 55(1-2):105-13. PubMed ID: 11955970
[TBL] [Abstract][Full Text] [Related]
8. Effects of olanzapine on auditory P300 and mismatch negativity (MMN) in schizophrenia spectrum disorders.
Korostenskaja M; Dapsys K; Siurkute A; Maciulis V; Ruksenas O; Kähkönen S
Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):543-8. PubMed ID: 15866356
[TBL] [Abstract][Full Text] [Related]
9. P300 subcomponent abnormalities in schizophrenia: II. Longitudinal stability and relationship to symptom change.
Turetsky B; Colbath EA; Gur RE
Biol Psychiatry; 1998 Jan; 43(1):31-9. PubMed ID: 9442342
[TBL] [Abstract][Full Text] [Related]
10. State and trait markers of emotionally charged visual event-related potentials (P300) in drug-naïve schizophrenia.
Mori K; Morita K; Shoji Y; Matsuoka T; Fujiki R; Uchimura N
Psychiatry Clin Neurosci; 2012 Jun; 66(4):261-9. PubMed ID: 22624730
[TBL] [Abstract][Full Text] [Related]
11. Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study.
Mathalon DH; Ford JM; Pfefferbaum A
Biol Psychiatry; 2000 Mar; 47(5):434-49. PubMed ID: 10704955
[TBL] [Abstract][Full Text] [Related]
12. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Citrome L; Volavka J; Czobor P; Sheitman B; Lindenmayer JP; McEvoy J; Cooper TB; Chakos M; Lieberman JA
Psychiatr Serv; 2001 Nov; 52(11):1510-4. PubMed ID: 11684748
[TBL] [Abstract][Full Text] [Related]
13. Auditory and visual P300 reflecting cognitive improvement in patients with schizophrenia with quetiapine: a pilot study.
Park EJ; Han SI; Jeon YW
Prog Neuropsychopharmacol Biol Psychiatry; 2010 May; 34(4):674-80. PubMed ID: 20304022
[TBL] [Abstract][Full Text] [Related]
14. Do atypical antipsychotics fail to exert cognitive sparing effects?
Papageorgiou C; Oulis P; Vasios C; Matsopoulos GK; Uzunoglu N; Rabavilas A; Christodoulou GN
Neuroreport; 2003 Mar; 14(3):505-9. PubMed ID: 12634513
[TBL] [Abstract][Full Text] [Related]
15. P300 subcomponents and clinical symptoms in schizophrenia.
Frodl T; Meisenzahl EM; Müller D; Holder J; Juckel G; Möller HJ; Hegerl U
Int J Psychophysiol; 2002 Mar; 43(3):237-46. PubMed ID: 11850089
[TBL] [Abstract][Full Text] [Related]
16. Auditory event-related potentials, auditory digit span, and clinical symptoms in chronic schizophrenic men on neuroleptic medication.
Stefánsson SB; Jónsdóttir TJ
Biol Psychiatry; 1996 Jul; 40(1):19-27. PubMed ID: 8780851
[TBL] [Abstract][Full Text] [Related]
17. P300 subcomponent abnormalities in schizophrenia: I. Physiological evidence for gender and subtype specific differences in regional pathology.
Turetsky BI; Colbath EA; Gur RE
Biol Psychiatry; 1998 Jan; 43(2):84-96. PubMed ID: 9474441
[TBL] [Abstract][Full Text] [Related]
18. [ERPs changes during neuroleptic treatment in schizophrenia--a vulnerability marker in schizophrenia].
Asato N; Hirayasu Y; Hiramatsu K; Ohta H
Seishin Shinkeigaku Zasshi; 1999; 101(3):254-76. PubMed ID: 10375977
[TBL] [Abstract][Full Text] [Related]
19. N100 and P300 amplitude to Go and No-Go variants of the auditory oddball in siblings discordant for schizophrenia.
Sumich A; Kumari V; Dodd P; Ettinger U; Hughes C; Zachariah E; Sharma T
Schizophr Res; 2008 Jan; 98(1-3):265-77. PubMed ID: 18022352
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300.
Higuchi Y; Sumiyoshi T; Kawasaki Y; Matsui M; Arai H; Kurachi M
Schizophr Res; 2008 Apr; 101(1-3):320-30. PubMed ID: 18321680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
